Jon T Giles1, Sonye K Danoff2, Jeremy Sokolove3, Catriona A Wagner3, Robert Winchester1, Dimitrios A Pappas1, Stanley Siegelman2, Geoff Connors4, William H Robinson3, Joan M Bathon1. 1. Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, New York, USA. 2. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA. 3. Veterans Administration Palo Alto Health Care System, Palo Alto, California, USA Division of Rheumatology, Stanford University, Stanford, California, USA. 4. Division of Pulmonary and Critical Care Medicine, Yale University, New Haven, Connecticut, USA.
Abstract
BACKGROUND: Interstitial lung disease (ILD) is associated with high morbidity and mortality in rheumatoid arthritis (RA). Citrullinated proteins are observed in RA lung tissues; however, the association of specific anticitrullinated peptide antibodies (ACPA) with ILD in RA is unknown. METHODS: RA patients underwent multidetector CT (MDCT) of the chest, from which ILD features and a semiquantitative ILD Score (ILDS; range 0-32) were assessed. Anti-CCP (CCP2) and levels of a panel of antibodies against 17 citrullinated and four non-citrullinated peptides were assessed from concurrent serum samples using a custom Bio-Plex bead array. High level ACPA was defined as ≥the group 75th percentile. RESULTS: Among the 177 RA patients studied, median levels of CCP2 and all specific ACPAs were 46-273% higher among RA patients with versus those without ILD (all p values <0.05), and higher levels correlated with higher ILDS. In contrast, levels of non-citrullinated protein antibodies were not higher in those with ILD. RA patients had a median of 2 high level ACPA reactivities (range 0-16), with each high level ACPA associated, on average, with a 0.10 unit higher ILDS (p=0.001). This association remained significant after adjusting for characteristics associated with ILD (age, gender, current and former smoking, Disease Activity Score for 28 joints, current prednisone and leflunomide use). More high level ACPA were observed in those with versus without pulmonary function restriction or impaired diffusion. CONCLUSIONS: Our findings of a broader ACPA repertoire in RA ILD suggest a possible role for ACPA in the pathogenesis of ILD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Interstitial lung disease (ILD) is associated with high morbidity and mortality in rheumatoid arthritis (RA). Citrullinated proteins are observed in RA lung tissues; however, the association of specific anticitrullinated peptide antibodies (ACPA) with ILD in RA is unknown. METHODS:RApatients underwent multidetector CT (MDCT) of the chest, from which ILD features and a semiquantitative ILD Score (ILDS; range 0-32) were assessed. Anti-CCP (CCP2) and levels of a panel of antibodies against 17 citrullinated and four non-citrullinated peptides were assessed from concurrent serum samples using a custom Bio-Plex bead array. High level ACPA was defined as ≥the group 75th percentile. RESULTS: Among the 177 RApatients studied, median levels of CCP2 and all specific ACPAs were 46-273% higher among RApatients with versus those without ILD (all p values <0.05), and higher levels correlated with higher ILDS. In contrast, levels of non-citrullinated protein antibodies were not higher in those with ILD. RApatients had a median of 2 high level ACPA reactivities (range 0-16), with each high level ACPA associated, on average, with a 0.10 unit higher ILDS (p=0.001). This association remained significant after adjusting for characteristics associated with ILD (age, gender, current and former smoking, Disease Activity Score for 28 joints, current prednisone and leflunomide use). More high level ACPA were observed in those with versus without pulmonary function restriction or impaired diffusion. CONCLUSIONS: Our findings of a broader ACPA repertoire in RA ILD suggest a possible role for ACPA in the pathogenesis of ILD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: K B Baumgartner; J M Samet; D B Coultas; C A Stidley; W C Hunt; T V Colby; J A Waldron Journal: Am J Epidemiol Date: 2000-08-15 Impact factor: 4.897
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: Jeremy Sokolove; Reuven Bromberg; Kevin D Deane; Lauren J Lahey; Lezlie A Derber; Piyanka E Chandra; Jess D Edison; William R Gilliland; Robert J Tibshirani; Jill M Norris; V Michael Holers; William H Robinson Journal: PLoS One Date: 2012-05-25 Impact factor: 3.240
Authors: Amanda L Lusa; Isabelle Amigues; Henry R Kramer; Thuy-Tien Dam; Jon T Giles Journal: Arthritis Care Res (Hoboken) Date: 2015-01 Impact factor: 4.794
Authors: Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Larry W Moreland Journal: Am J Epidemiol Date: 2014-02-24 Impact factor: 4.897
Authors: Tracy J Doyle; Avignat S Patel; Hiroto Hatabu; Mizuki Nishino; Guodong Wu; Juan C Osorio; Maria F Golzarri; Andres Traslosheros; Sarah G Chu; Michelle L Frits; Christine K Iannaccone; Diane Koontz; Carl Fuhrman; Michael E Weinblatt; Souheil Y El-Chemaly; George R Washko; Gary M Hunninghake; Augustine M K Choi; Paul F Dellaripa; Chester V Oddis; Nancy A Shadick; Dana P Ascherman; Ivan O Rosas Journal: Am J Respir Crit Care Med Date: 2015-06-15 Impact factor: 21.405
Authors: José Félix Restrepo; Inmaculada del Rincón; Daniel F Battafarano; Roy W Haas; Merced Doria; Agustín Escalante Journal: Clin Rheumatol Date: 2015-08-09 Impact factor: 2.980